PET-MR Imaging Using 64Cu-25%-CANF-Comb to Study Natriuretic Peptide Receptor C in Adults with Asymptomatic Carotid Artery Stenosis

What this Trial Is About

Researchers are studying plaque biology in patients with asymptomatic carotid artery stenosis ACAS using advanced imaging techniques. This observational study aims to assess whether 64Cu-CANF-Comb positron emission tomography PET combined with magnetic resonance imaging MRI can help predict stroke risk or related events in ACAS patients. The study also seeks to better understand the role of Natriuretic Peptide Receptor C NPRC in the progression of carotid artery atherosclerosis. Participants will receive an intravenous injection of 2-6 milliCuries of the 64Cu-25%-CANF-Comb radiotracer approved for investigational use. They will undergo a carotid PETMRI scan 12 to 24 hours after injection to evaluate plaque uptake. Patients treated with optimal medical therapy OMT alone will have a repeat PETMRI 12 to 18 months later or sooner if symptoms develop, while those treated with OMT and carotid endarterectomy CEA will have imaging only once. The study enrolls 80 subjects with carotid artery narrowing of 60% or more. During the study, participants will have baseline assessments including physical exams, blood and urine tests, and vital sign measurements. Researchers will collect medication and risk factor information, and follow up by phone every three months for up to four years to monitor for stroke, transient ischemic attack, or carotid interventions. Imaging results and clinical outcomes will help evaluate the potential of PETMRI to stratify stroke risk and understand carotid plaque biology over time.

CANF-Comb-II PET-MR in Atherosclerosis Multisite